K. Tomasiewicz, A. Dębska-Ślizień, M. Durlik, K. Giannopoulos, I. Hus, P. Rutkowski
{"title":"Recommendations for prevention of SARS-CoV-2 infection in immunocompromised patients","authors":"K. Tomasiewicz, A. Dębska-Ślizień, M. Durlik, K. Giannopoulos, I. Hus, P. Rutkowski","doi":"10.5603/ocp.2022.0035","DOIUrl":"https://doi.org/10.5603/ocp.2022.0035","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72407723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Pogoda, A. Jagiełło-Gruszfeld, M. Kunkiel, W. Olszewski
{"title":"Atezolizumab in the treatment of patients with breast cancer","authors":"K. Pogoda, A. Jagiełło-Gruszfeld, M. Kunkiel, W. Olszewski","doi":"10.5603/ocp.2022.0036","DOIUrl":"https://doi.org/10.5603/ocp.2022.0036","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91206322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Niraparib maintenance in newly diagnosed advanced ovarian cancer — review and case series","authors":"Martyna Tyszka, R. Stec","doi":"10.5603/ocp.2022.0048","DOIUrl":"https://doi.org/10.5603/ocp.2022.0048","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78067076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Dębska-Szmich, M. Krakowska, Katarzyna Staniecka, Paulina Krzeptowska, Jakub Dębski, Maria Dzierżak, M. Wąsik, Joanna Gadzinowska, Maja Habib-Lisik
{"title":"Overall survival of patients with metastatic KRAS wild type colorectal cancer patients treated with anti-EGFR third line monotherapy","authors":"S. Dębska-Szmich, M. Krakowska, Katarzyna Staniecka, Paulina Krzeptowska, Jakub Dębski, Maria Dzierżak, M. Wąsik, Joanna Gadzinowska, Maja Habib-Lisik","doi":"10.5603/ocp.2022.0044","DOIUrl":"https://doi.org/10.5603/ocp.2022.0044","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74674159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Rutkowski, P. Wysocki, K. Kozak, A. Nasierowska-Guttmejer, A. Jeziorski, W. Wysocki, E. Kalinka, T. Świtaj, G. Kamińska-Winciorek, A. Czarnecka, H. Koseła-Paterczyk, B. Cybulska-Stopa, Piotr Wiśniewski, A. Szumera-Ciećkiewicz, M. Zdzienicki, M. Ziobro, J. Fijuth, A. Kawecki, A. Tysarowski, B. Romanowska-Dixon, A. Markiewicz, M. Dedecjus, T. Kubiatowski, Kamil Dolecki, Hanna Tchórzewska-Korba, L. Rudnicka, W. Owczarek, M. Krzakowski
{"title":"Expert recommendations on diagnostic-therapeutic management of melanoma patients","authors":"P. Rutkowski, P. Wysocki, K. Kozak, A. Nasierowska-Guttmejer, A. Jeziorski, W. Wysocki, E. Kalinka, T. Świtaj, G. Kamińska-Winciorek, A. Czarnecka, H. Koseła-Paterczyk, B. Cybulska-Stopa, Piotr Wiśniewski, A. Szumera-Ciećkiewicz, M. Zdzienicki, M. Ziobro, J. Fijuth, A. Kawecki, A. Tysarowski, B. Romanowska-Dixon, A. Markiewicz, M. Dedecjus, T. Kubiatowski, Kamil Dolecki, Hanna Tchórzewska-Korba, L. Rudnicka, W. Owczarek, M. Krzakowski","doi":"10.5603/ocp.2021.0042","DOIUrl":"https://doi.org/10.5603/ocp.2021.0042","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90565296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Kolasińska-Ćwikła, Klaudia Gutowska, K. Osowiecka, T. Bednarczuk, Anna Słoniewska, K. Roszkowska-Purska, J. Pałucki, J. Cwikła
Introduction. Somatostatin analogs (SSA) are widely used in the treatment of patients with well-differentiated neuroendocrine tumors (NET). There are limited reports about the role of octreotide LAR in first-line therapy of advanced pancreatic NET (pan-NET). This study aimed to evaluate the antiproliferative effect of octreotide LAR in patients with sporadic, advanced, unresectable pan-NET, based on progression-free survival (PFS). Material and methods. This was a retrospective analysis of 374 patients with pan-NET; 41 treated subjects were included. The primary endpoint was PFS defined as the time to disease progression (Response Evaluation Criteria in Solid Tumors: RECIST). Univariate and multivariate analyses were used to identify predictors of PFS. Secondary endpoints included overall survival (OS) and second-line therapies after progression. Results. There were 13 (32%) patients with G1 pan-NET and 28 (68%) with pan-NET G2, 21 female and 20 male, with mean age 55.4 (range 29–87). Median PFS was 9.0 months (95% CI 4.7–24.0). Subgroup analysis revealed that G1 and no-bulky liver disease (< 25% liver volume) were associated with significantly longer PFS. Univariate analysis confirmed a correlation between G1 [0.34 hazard rate (HR) of progression or death (95% CI 0.16–0.72)] and no-bulky liver disease HR = 0.31 (95% CI 0.13–0.71). Multivariable analysis demonstrated that only functional (secretory) pan-NET was associated as an independent factor with shorter PFS HR = 2.97 (95% CI 1.0–8.74). Median OS was 105.4 months (95% CI 40.0–172.0). After relapse following initial systemic therapy, the second line was used in 34 subjects, 3rd line in 18th, and 4th line in 9 subjects. Conclusions. Octreotide LAR shows moderate antiproliferative activity in pan-NET. Prolonged PFS may be associated with G1 and low-volume metastatic liver disease. In patients with progressive disease, various treatment options were used, which resulted in median OS of 105.4 months.
介绍。生长抑素类似物(SSA)广泛应用于高分化神经内分泌肿瘤(NET)患者的治疗。关于奥曲肽LAR在晚期胰腺NET (pan-NET)一线治疗中的作用的报道有限。本研究旨在基于无进展生存期(PFS)评估奥曲肽LAR对散发、晚期、不可切除的pan-NET患者的抗增殖作用。材料和方法。这是一项对374例pan-NET患者的回顾性分析;纳入41名治疗对象。主要终点是PFS，定义为疾病进展的时间(实体肿瘤反应评价标准:RECIST)。采用单因素和多因素分析来确定PFS的预测因素。次要终点包括总生存期(OS)和进展后的二线治疗。结果。G1期pan-NET 13例(32%)，G2期pan-NET 28例(68%)，女性21例，男性20例，平均年龄55.4岁(29-87岁)。中位PFS为9.0个月(95% CI 4.7-24.0)。亚组分析显示，G1和无大体积肝病(肝体积< 25%)与PFS显著延长相关。单因素分析证实G1[进展或死亡的0.34危险率(HR) (95% CI 0.16-0.72)]与非大体积肝病的HR = 0.31 (95% CI 0.13-0.71)之间存在相关性。多变量分析表明，只有功能性(分泌)pan-NET与较短的PFS HR相关(95% CI 1.0-8.74)。中位OS为105.4个月(95% CI 40.0-172.0)。初次全身治疗后复发的34例患者采用二线治疗，18例采用三线治疗，9例采用四线治疗。结论。奥曲肽LAR在pan-NET中表现出中等的抗增殖活性。PFS延长可能与G1和小体积转移性肝病有关。对于病情进展的患者，采用了多种治疗方案，中位OS为105.4个月。
{"title":"Evaluation of survival outcomes in patients with sporadic, advanced, unresectable well-differentiated pancreatic neuroendocrine tumors treated initially with octreotide LAR and subsequent therapeutical approaches on relapse. A real-world data set","authors":"A. Kolasińska-Ćwikła, Klaudia Gutowska, K. Osowiecka, T. Bednarczuk, Anna Słoniewska, K. Roszkowska-Purska, J. Pałucki, J. Cwikła","doi":"10.5603/ocp.2022.0045","DOIUrl":"https://doi.org/10.5603/ocp.2022.0045","url":null,"abstract":"Introduction. Somatostatin analogs (SSA) are widely used in the treatment of patients with well-differentiated neuroendocrine tumors (NET). There are limited reports about the role of octreotide LAR in first-line therapy of advanced pancreatic NET (pan-NET). This study aimed to evaluate the antiproliferative effect of octreotide LAR in patients with sporadic, advanced, unresectable pan-NET, based on progression-free survival (PFS). Material and methods. This was a retrospective analysis of 374 patients with pan-NET; 41 treated subjects were included. The primary endpoint was PFS defined as the time to disease progression (Response Evaluation Criteria in Solid Tumors: RECIST). Univariate and multivariate analyses were used to identify predictors of PFS. Secondary endpoints included overall survival (OS) and second-line therapies after progression. Results. There were 13 (32%) patients with G1 pan-NET and 28 (68%) with pan-NET G2, 21 female and 20 male, with mean age 55.4 (range 29–87). Median PFS was 9.0 months (95% CI 4.7–24.0). Subgroup analysis revealed that G1 and no-bulky liver disease (< 25% liver volume) were associated with significantly longer PFS. Univariate analysis confirmed a correlation between G1 [0.34 hazard rate (HR) of progression or death (95% CI 0.16–0.72)] and no-bulky liver disease HR = 0.31 (95% CI 0.13–0.71). Multivariable analysis demonstrated that only functional (secretory) pan-NET was associated as an independent factor with shorter PFS HR = 2.97 (95% CI 1.0–8.74). Median OS was 105.4 months (95% CI 40.0–172.0). After relapse following initial systemic therapy, the second line was used in 34 subjects, 3rd line in 18th, and 4th line in 9 subjects. Conclusions. Octreotide LAR shows moderate antiproliferative activity in pan-NET. Prolonged PFS may be associated with G1 and low-volume metastatic liver disease. In patients with progressive disease, various treatment options were used, which resulted in median OS of 105.4 months.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76730247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Diptajit Paul, Sheeba Bhardwaj, G. Yadav, V. Kaushal
{"title":"Aggressiveness of esthesioneuroblastoma: a rare case report and review of literature","authors":"Diptajit Paul, Sheeba Bhardwaj, G. Yadav, V. Kaushal","doi":"10.5603/ocp.2022.0041","DOIUrl":"https://doi.org/10.5603/ocp.2022.0041","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81790950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Synchronous case of cutaneous melanoma and gallbladder cancer in a 74-year-old female patient","authors":"M. Witek, Aleksandra Lasek","doi":"10.5603/ocp.2022.0046","DOIUrl":"https://doi.org/10.5603/ocp.2022.0046","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75100364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：